Phase IA Study of Atezolizumab in Urothelial Bladder Cancer

June 26, 2015
Daniel Petrylak, MD

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and of Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses a phase Ia study examining atezolizumab in patients with urothelial bladder cancer.